TG Therapeutics Inc
NASDAQ:TGTX

Watchlist Manager
TG Therapeutics Inc Logo
TG Therapeutics Inc
NASDAQ:TGTX
Watchlist
Price: 34.57 USD 0.96% Market Closed
Market Cap: 5.4B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

TGTX Price Targets Summary
TG Therapeutics Inc

Wall Street analysts forecast TGTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TGTX is 43.35 USD with a low forecast of 11.11 USD and a high forecast of 57.75 USD.

TGTX Lowest Forecast
Wall Street Target
11.11 USD
68% Downside
TGTX Average Forecast
Wall Street Target
43.35 USD
25% Upside
TGTX Highest Forecast
Wall Street Target
57.75 USD
67% Upside
Lowest
Price Target
11.11 USD
68% Downside
Average
Price Target
43.35 USD
25% Upside
Highest
Price Target
57.75 USD
67% Upside
TG Therapeutics Inc Competitors:
Price Targets
A
ACLX
Arcellx Inc
84% Upside
A
ARMP
Armata Pharmaceuticals Inc
278% Upside
PEB
Pacific Edge Ltd
19% Downside
TSHA
Taysha Gene Therapies Inc
150% Upside
A
ACLX
Arcellx Inc
84% Upside
A
ARMP
Armata Pharmaceuticals Inc
278% Upside
PEB
Pacific Edge Ltd
19% Downside
TSHA
Taysha Gene Therapies Inc
150% Upside
IMMX
Immix Biopharma Inc
259% Upside
2171
CARsgen Therapeutics Holdings Ltd
55% Downside
1530
3SBio Inc
36% Downside
4974
Takara Bio Inc
40% Upside

Revenue
Forecast

Revenue Estimate
TG Therapeutics Inc

For the last 8 years the compound annual growth rate for TG Therapeutics Inc's revenue is 161%. The projected CAGR for the next 3 years is 48%.

161%
Past Growth
48%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
TG Therapeutics Inc

The compound annual growth rate of TG Therapeutics Inc's operating income for the next 3 years is 127%.

N/A
Past Growth
127%
Estimated Growth
Estimates Accuracy
7%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
TG Therapeutics Inc

The compound annual growth rate of TG Therapeutics Inc's net income for the next 3 years is 157%.

N/A
Past Growth
157%
Estimated Growth
Estimates Accuracy
-24%
Average Miss
What are analyst estimates?

See Also

Summary
TGTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
TGTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TGTX stock valuation using valuation multiples.
Wall Street Estimates
TGTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TGTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TGTX's stock price target?
Price Target
43.35 USD

According to Wall Street analysts, the average 1-year price target for TGTX is 43.35 USD with a low forecast of 11.11 USD and a high forecast of 57.75 USD.

What is TG Therapeutics Inc's Revenue forecast?
Projected CAGR
48%

For the last 8 years the compound annual growth rate for TG Therapeutics Inc's revenue is 161%. The projected CAGR for the next 3 years is 48%.

What is TG Therapeutics Inc's Operating Income forecast?
Projected CAGR
127%

The compound annual growth rate of TG Therapeutics Inc's operating income for the next 3 years is 127%.

What is TG Therapeutics Inc's Net Income forecast?
Projected CAGR
157%

The compound annual growth rate of TG Therapeutics Inc's net income for the next 3 years is 157%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 257,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.